Tuesday June 25, 2019

Blocking Digestive Hormone May Prevent Pancreatic Cancer

The team explained that pancreatic growth and regeneration occurs through interaction of CCK with CCK receptors, proteins that bind to CCK to produce a physiological reaction

0
//
stomach
5 herbs for a healthy digestive system. Pixabay

Blocking a digestive hormone associated with obesity may help prevent the spread of pancreatic tumours to other areas in the body, according to a study.

A high-fat diet promotes the growth of pancreatic cancer independent of obesity because of the interaction between dietary fat and cholecystokinin (CCK) — digestive hormone released by the small intestine. The hormone secretion gets further triggered by the fatty diet.

Previous research has shown that obesity and high-fat diets both together and independently increase the risk of pancreatic cancer.

“Most patients with advanced pancreatic cancer succumb to the disease due to metastases; therefore a compound that blocks metastases, even when the primary tumour size is large, may have clinical significance,” said the researchers including Jill Smith from the Georgetown University in the US.

“CCK [receptor] blockade may play a role in the treatment and prevention of pancreatic cancer,” they added.

Previous research has shown that obesity and high-fat diets both together and independently increase the risk of pancreatic cancer.
Previous research has shown that obesity and high-fat diets both together and independently increase the risk of pancreatic cancer. Pixabay

For the study, published in American Journal of Physiology-Gastrointestinal and Liver Physiology, the team fed one group of mice with high-fat diet while the other half were given a normal diet. Then some of them were treated with proglumide — a medication that blocks CCK.

The results showed that mice treated with proglumide had less tumour growth than the untreated mice, even when fed a high-fat diet.

Further, they found that among high-fat diet-fed mice lacking CCK receptors did not show any tumour growth, suggesting that without receptors to bind to, increased CCK from dietary fat is unable to promote cancer.

Also Read: More Women Falling Prey to Lung Cancer: Study

The team explained that pancreatic growth and regeneration occurs through interaction of CCK with CCK receptors, proteins that bind to CCK to produce a physiological reaction.

Proglumide treatment also protected the mice from the development of excessive fibrous tissue — fibrosis — that can be associated with cancer metastases and resistance to chemotherapy, the researchers said. (IANS)

Next Story

Researchers Discover Balance of Two Enzymes That May Help Treat Pancreatic Cancer

While still in the earliest stages, Newton hoped this information might one day aid pancreatic diagnostics and treatment

0
Cancer
Cancer Ribbon. Pixabay

A new research has set the stage for clinicians to potentially use levels of a pancreatic cancer patient’s PHLPP1 and PKC enzymes as a prognostic and for researchers to develop new therapeutic drugs that change the balance of the two enzymes as a means to treat the disease.

The study, published on Wednesday in Molecular Cell, was led by Alexandra Newton, professor in the Department of Pharmacology at the University of California, San Diego, School of Medicine, and Timothy Baffi, a graduate student in her lab, Xinhua news agency reported.

The new study built on the team’s work in 2015 that found the enzyme PKC, which was believed in previous studies to promote tumour growth, actually suppressed it.

The latest study took the investigation a step further by uncovering how cells regulate PKC activity and discovered that any time an over-active PKC is inadvertently produced, the PHLPP1 “proofreader” tags it for destruction.

Cancer patient
Cancer patient.

“That means the amount of PHLPP1 in your cells determines your amount of PKC,” Newton said. “And it turns out those enzyme levels are especially important in pancreatic cancer.”

The team observed 105 pancreatic cancer tumours to analyze the enzyme levels in each one. About 50 per cent of patients with low PHLPP1/high PKC lived longer than five-and-a-half years.

Also Read- A Brain Circuit Can Help Reverse Craving for Liquor, Says Study

While still in the earliest stages, Newton hoped this information might one day aid pancreatic diagnostics and treatment.

Pancreatic cancer is caused by the abnormal and uncontrolled growth of cells in the pancreas, a large gland in the digestive system. It typically doesn’t show symptoms in the early stages. Sufferers tend to develop signs, such as back pain and jaundice, when it has spread to other organs. (IANS)